CA3037146A1 - Method of reducing thyroid-associated side effects - Google Patents
Method of reducing thyroid-associated side effects Download PDFInfo
- Publication number
- CA3037146A1 CA3037146A1 CA3037146A CA3037146A CA3037146A1 CA 3037146 A1 CA3037146 A1 CA 3037146A1 CA 3037146 A CA3037146 A CA 3037146A CA 3037146 A CA3037146 A CA 3037146A CA 3037146 A1 CA3037146 A1 CA 3037146A1
- Authority
- CA
- Canada
- Prior art keywords
- optionally substituted
- group
- days
- alkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fats And Perfumes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662396015P | 2016-09-16 | 2016-09-16 | |
| US201662396025P | 2016-09-16 | 2016-09-16 | |
| US62/396,025 | 2016-09-16 | ||
| US62/396,015 | 2016-09-16 | ||
| PCT/US2017/051410 WO2018053036A1 (en) | 2016-09-16 | 2017-09-13 | Method of reducing thyroid-associated side effects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3037146A1 true CA3037146A1 (en) | 2018-03-22 |
Family
ID=61619247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3037146A Pending CA3037146A1 (en) | 2016-09-16 | 2017-09-13 | Method of reducing thyroid-associated side effects |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20190255080A1 (enExample) |
| EP (1) | EP3512523A4 (enExample) |
| JP (2) | JP2019531346A (enExample) |
| KR (2) | KR20240074912A (enExample) |
| CN (2) | CN121695155A (enExample) |
| AU (1) | AU2017327383B2 (enExample) |
| CA (1) | CA3037146A1 (enExample) |
| MX (2) | MX2019003032A (enExample) |
| WO (1) | WO2018053036A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008542301A (ja) | 2005-05-26 | 2008-11-27 | メタバシス・セラピューティクス・インコーポレイテッド | 脂肪性肝疾患の処置のための甲状腺ホルモン様薬剤 |
| EP3541395A4 (en) | 2016-11-21 | 2020-07-01 | Viking Therapeutics, Inc. | GLYCOGENOSIS TREATMENT METHODS |
| EP3634426A4 (en) | 2017-06-05 | 2021-04-07 | Viking Therapeutics, Inc. | COMPOSITIONS FOR TREATMENT OF FIBROSE |
| CA3094167A1 (en) | 2018-03-22 | 2019-09-26 | Viking Therapeutics, Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
| WO2020117962A1 (en) | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| BR112021021923A2 (pt) * | 2019-05-08 | 2022-02-22 | Novartis Ag | Anticorpos anti-cd40 para uso no tratamento de dm1 e insulite |
| RU2728261C2 (ru) * | 2019-05-22 | 2020-07-28 | Ирина Алексеевна Курникова | Способ дифференциальной диагностики йоддефицитного и йодиндуцированного нарушения функции щитовидной железы у лиц, проживающих в регионах с йодным дефицитом |
| CN112457346B (zh) * | 2019-08-19 | 2022-09-06 | 和博医药有限公司 | 一种并环THRβ受体激动剂化合物及其制备方法和用途 |
| US12378268B2 (en) | 2019-08-19 | 2025-08-05 | Hepagene Therapeutics (HK) Limited | Heterocyclic THR-β receptor agonist compound and preparation method and use therefor |
| JP7670687B2 (ja) * | 2020-02-24 | 2025-04-30 | へパジーン セラピューティクス （エイチケイ） リミテッド | 複素環式ＴＨＲ－β受容体アゴニスト化合物ならびにその調製方法および使用 |
| US11752161B2 (en) | 2020-03-27 | 2023-09-12 | Gannex Pharma Co., Ltd. | Pharmaceutical compositions, method of making and method of using thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| MXPA04012497A (es) * | 2002-07-04 | 2005-07-14 | Zealand Pharma As | Glp-1 y metodos para tratar la diabetes. |
| US7829552B2 (en) | 2003-11-19 | 2010-11-09 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyromimetics |
| JP2008542301A (ja) * | 2005-05-26 | 2008-11-27 | メタバシス・セラピューティクス・インコーポレイテッド | 脂肪性肝疾患の処置のための甲状腺ホルモン様薬剤 |
| WO2009089093A1 (en) * | 2008-01-04 | 2009-07-16 | Quatrx Pharmaceuticals Company | Thyroid hormone receptor agonists |
| CA2732686C (en) * | 2008-12-22 | 2017-10-03 | Otonomy, Inc. | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
| WO2011038207A1 (en) * | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| US20170319604A1 (en) * | 2016-04-22 | 2017-11-09 | Metabasis Therapeutics, Inc. | Thyroid hormone receptor agonist and use thereof |
-
2017
- 2017-09-13 MX MX2019003032A patent/MX2019003032A/es unknown
- 2017-09-13 US US16/333,513 patent/US20190255080A1/en active Pending
- 2017-09-13 CN CN202511838413.1A patent/CN121695155A/zh active Pending
- 2017-09-13 CA CA3037146A patent/CA3037146A1/en active Pending
- 2017-09-13 KR KR1020247016178A patent/KR20240074912A/ko active Pending
- 2017-09-13 KR KR1020197010782A patent/KR20190060786A/ko not_active Ceased
- 2017-09-13 EP EP17851476.6A patent/EP3512523A4/en active Pending
- 2017-09-13 AU AU2017327383A patent/AU2017327383B2/en active Active
- 2017-09-13 WO PCT/US2017/051410 patent/WO2018053036A1/en not_active Ceased
- 2017-09-13 CN CN201780068418.8A patent/CN109922812A/zh active Pending
- 2017-09-13 JP JP2019536463A patent/JP2019531346A/ja active Pending
-
2019
- 2019-03-15 MX MX2023000887A patent/MX2023000887A/es unknown
-
2022
- 2022-09-16 JP JP2022148311A patent/JP7656574B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019531346A (ja) | 2019-10-31 |
| EP3512523A4 (en) | 2020-05-06 |
| US20190255080A1 (en) | 2019-08-22 |
| NZ751857A (en) | 2024-05-31 |
| MX2023000887A (es) | 2023-02-22 |
| MX2019003032A (es) | 2019-09-13 |
| JP2022174261A (ja) | 2022-11-22 |
| KR20240074912A (ko) | 2024-05-28 |
| BR112019005039A2 (pt) | 2019-06-25 |
| AU2017327383A1 (en) | 2019-04-11 |
| CN109922812A (zh) | 2019-06-21 |
| EP3512523A1 (en) | 2019-07-24 |
| CN121695155A (zh) | 2026-03-20 |
| AU2017327383B2 (en) | 2023-06-29 |
| JP7656574B2 (ja) | 2025-04-03 |
| WO2018053036A1 (en) | 2018-03-22 |
| KR20190060786A (ko) | 2019-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3037146A1 (en) | Method of reducing thyroid-associated side effects | |
| AU2019394947B2 (en) | Compositions and methods for the treatment of liver disorders | |
| US11524930B2 (en) | Substituted aromatic compounds and related method for the treatment of fibrosis | |
| JP2016185957A (ja) | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター | |
| JP2021059574A (ja) | 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤 | |
| US11202789B2 (en) | Method of treating glycogen storage disease | |
| AU2018280118A1 (en) | Compositions for the treatment of fibrosis | |
| US20100222376A1 (en) | Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders | |
| US11311508B2 (en) | Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis | |
| JP2018090589A (ja) | 肝機能改善法 | |
| JPH06279397A (ja) | アミノ酸系末梢神経障害改善剤 | |
| BR112019005039B1 (pt) | Método de redução dos efeitos colaterais associados à tireoide | |
| EP4166137A1 (en) | Therapeutic agent for fatty liver disease | |
| HK40031634A (en) | Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis | |
| EA042390B1 (ru) | Способ терапевтического лечения фиброза |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220912 |
|
| EEER | Examination request |
Effective date: 20220912 |
|
| EEER | Examination request |
Effective date: 20220912 |
|
| EEER | Examination request |
Effective date: 20220912 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240813 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240813 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240813 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240821 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240821 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240821 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20240919 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250115 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250311 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250311 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW Effective date: 20250409 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250409 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250410 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250526 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250526 |